Time to Scalp Hair, Eyebrow, and Eyelash Improvement in Patients with Alopecia Areata Treated with Baricitinib in the Phase 2 Portion of the Phase 2/3 BRAVE-AA1 Study

August 2021 in “ Journal of The American Academy of Dermatology ”

Maryanne M. Senna, Amy J. McMichael, Tiffany T. Mayo, Julian Mackay‐Wiggan, Marc Glashofer, Luna Sun, Guanglei Yu, Fabio P. Nunes, Jill Shwed McCollam, Wen‐Chi Wu, Brett King

baricitinib JAK1/JAK2 inhibitor alopecia areata Severity of Alopecia Tool SALT score hair regrowth eyebrow improvement eyelash improvement

TLDR Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.

The phase 2 of the BRAVE-AA1 study evaluated the effectiveness of baricitinib, a JAK1/JAK2 inhibitor, in treating alopecia areata (AA) patients. The study involved 82 participants divided into three groups: baricitinib 4-mg (27 participants), baricitinib 2-mg (27 participants), and placebo (28 participants). At week 36, 52% of the 4-mg group, 33% of the 2-mg group, and 4% of the placebo group achieved a Severity of Alopecia Tool (SALT) score ≤20, indicating hair regrowth. In terms of eyebrow and eyelash improvement, 39% and 60% of the 4-mg group, 29% and 40% of the 2-mg group, and 4% and 6% of the placebo group achieved eyebrow and eyelash scores ≤1, respectively. These results suggest that baricitinib may be an effective treatment for AA.

View this study on jaad.org →

Discuss this study in the Community →

Related Research

7 / 7 results

research Baricitinib Results in Eyebrow and Eyelash Growth in Patients With Alopecia Areata Who Do Not Achieve 20% or Less Scalp Hair Loss

1 citations, September 2022 in “Journal of The American Academy of Dermatology”

Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.

research Alopecia Areata After Severe Allergic Contact Dermatitis to a Permanent Hair Dye

August 2022 in “Contact dermatitis”

Severe allergic reactions to hair dye can trigger hair loss and may be linked to multiple sclerosis.

Time to Scalp Hair, Eyebrow, and Eyelash Improvement in Patients with Alopecia Areata Treated with Baricitinib in the Phase 2 Portion of the Phase 2/3 BRAVE-AA1 Study

research Time to Scalp Hair, Eyebrow, and Eyelash Improvement in Patients with Alopecia Areata Treated with Baricitinib in the Phase 2 Portion of the Phase 2/3 BRAVE-AA1 Study

1 citations, August 2021 in “Journal of The American Academy of Dermatology”

Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.

research Rare Presentation of Concomitant Alopecia Areata and Vitiligo in a Teenager

May 2021 in “Skin”

A teenager had both alopecia areata and vitiligo, which are rare to occur together.

research Hair Loss in Lichen Planopilaris and Frontal Fibrosing Alopecia: Not Always Irreversible

9 citations, January 2020 in “Skin appendage disorders”

Hair loss from conditions like LPP and FFA can potentially be reversed with the right treatment.

research Hair Disorders

August 2018 in “Oxford University Press eBooks”

The document's conclusion cannot be provided because the document cannot be parsed.

research Bimatoprost for the Treatment of Eyelash, Eyebrow, and Scalp Alopecia

38 citations, March 2017 in “Expert Opinion on Investigational Drugs”

Bimatoprost is promising for treating some types of hair loss but needs more testing for androgenetic alopecia.

Time to Scalp Hair, Eyebrow, and Eyelash Improvement in Patients with Alopecia Areata Treated with Baricitinib in the Phase 2 Portion of the Phase 2/3 BRAVE-AA1 Study

Related Community Posts Join

community What are the odds baricitinib will get a topical otc version for androgenic alopecia?

community Anyone heard of or have experience using baricitinib?

community Olumiant active ingredient Baricitinib

community Lilly to seek first approval of an autoimmune drug for hair loss

community Does a minoxidil tester exist? To test if whatever you get is actually minoxidil or some fake?

community I am a dermatologist with a clinical interest in alopecia. AMA